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Introduction
Myasthenia gravis (MG), which is characterized by fatigability 
and fluctuating weakness of the skeletal muscles, was one of the 
neurological diseases with a serious prognosis in the past, as in-
dicated by the origin of its name. MG is probably the best un-
derstood one of the autoimmune disorders of the nervous sys-
tem. The main pathogenesis of MG is the loss of acetylcholine 
receptors (AChRs) on the postsynaptic membrane of the neu-
romuscular junction (NMJ) as a result of the production of AChR 
antibodies (Abs), although other antigens are subject to immune 
attack in a small number of patients.
1-3 Based on the clinical man-
ifestation, the disease is usually classified into ocular MG and 
generalized MG. Ocular MG affects only the extraocular mus-
cles, whereas generalized MG affects other muscles beyond the 
ocular muscles, and may include limb, bulbar, facial and respi-
ratory muscles. Serologically, AChR Abs are detectable in ap-
proximately 50% of ocular-MG cases and 80-85% of general-
ized-MG cases.
1-3 Approximately 40% of generalized-MG pa-
tients who lack AChR Abs have been found to have Abs directed 
against the muscle-specific receptor tyrosine kinase (MuSK) 
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care medicine and symptomatic treatments. Its immunopathogenesis is fundamentally a T-cell-de-
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duce improvement within a few days after initiation, and so are useful for acute exacerbation 
including myasthenic crisis or in the perioperative period. High-dose prednisone has been more 
universally preferred for remission induction, but it acts more slowly than IVIg and PE, common-
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od of maintaining the state of remission. However, because of significant side effects, other immu-
nosuppressants (ISs) are frequently added as “steroid-sparing agents”. The currently available ISs 
exert their immunosuppressive effects by three mechanisms: 1) blocking the synthesis of DNA and 
RNA, 2) inhibiting T-cell activation and 3) depleting the B-cell population. In addition, newer drugs 
including antisense molecule, tumor necrosis factor alpha receptor blocker and complement inhibi-
tors are currently under investigation to confirm their effectiveness. Until now, the treatment of MG 
has been based primarily on experience rather than gold-standard evidence from randomized con-
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proved treatments.  J Clin Neurol 2011;7:173-183
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in the postsynaptic memebrane.
1-3 Patients who are negative for 
both AChR and MuSK Abs are now classified as “seronegative” 
MG.
Extensive analysis of the anti-AChR response in MG and in 
its experimental model, experimental autoimmune myasthenia 
gravis, has revealed that the autoimmune attack is dependent 
on T-cells, resulting from loss of tolerance toward self-antigens 
at the level of the thymus.
1-3 However, Abs and complements 
are the key effectors of the loss of postsynaptic AChRs and as-
sociated destruction of the NMJ.
1-3 Therefore, the goal of MG 
treatment is to interrupt the autoimmune process by T-cells and 
B-cells as soon as possible and thereby prevent further destruc-
tion of the NMJ. Since the introduction of corticosteroids (CSs) 
in the 1950s, immunomodulating therapies including thymecto-
my, intravenous immunoglobulin (IVIg), and some immuno-
suppressants (ISs) have been widely used. However, random-
ized controlled trials have been limited, perhaps because MG is a 
rare disease and it is difficult to recruit many proper patients. 
This may also be attributable to the lack of reliable and validat-
ed outcome measures. For this reason, most neurologists have cho-
sen immunotherapies available within their medical environments 
in light of their own clinical experiences. The aim of this article 
was to review and summarize the current strategies for MG treat-
ment and to introduce new therapeutic trials.
Symptom-Relieving Treatments
Non-selective acetylcholinesterase inhibitors
Acetylcholinesterase inhibitors (AChEIs) have been used ex-
tensively as a basic treatment and diagnostic tool for MG since 
1934. Their mechanism of action is competitive blockade of the 
enzyme AChE, which is located in the extracellular matrix of 
the folded postsynaptic muscle endplate membrane and breaks 
down ACh into the inactive metabolites choline and acetate. 
AChEIs therefore prolong the level and duration of action of 
the neurotransmitter ACh. AChEIs are generally effective in rel-
atively early or mild MG, in which patients have a sufficient 
number of remaining AChRs.
2 Several AChEIs are currently avail-
able, which are generally classified according to their duration 
of action. The most commonly used drug is pyridostigmine, which 
is available in 60-mg tablets and begins to work 30 minutes af-
ter oral administration, with the action duration of 3-6 hours.
1 
It is generally taken every 4 hours while awake. Its dosage should 
be adjusted to 60-960 mg/day depending upon the clinical re-
sponse and needs of the patient. The dosage is lower in patients 
with renal failure because it is excreted renally. Sustained-release 
tablets, taken at bedtime, are useful for patients with early-morn-
ing weakness, while the syrup formulation is helpful for children 
or patients with a nasogastric tube. AChEIs are well tolerated by 
most patients and are regarded as safe. Since AChEIs act on both 
muscarinic and nicotinic synapses, they induce the correspond-
ing adverse cholinergic effects.
1 The muscarinic effects include 
gastrointestinal tract hypermotility (e.g., abdominal pain and di-
arrhea), excessive salivation and respiratory secretions, increased 
sweating, and bradycardia or arrhythmia.
1 The nicotinic side 
effects are muscular fasciculation or twitching.
1 Overdose may 
give rise to serious cholinergic toxicity or crisis (e.g., flaccid pa-
ralysis or respiratory failure), which results from overstimulated 
neuromuscular transmission by excessive ACh.
1
Avoidance of drugs causing disturbance 
of neuromuscular transmission
Some drugs can cause disturbance of neuromuscular transmis-
sion by acting on the NMJ presynaptically or postsynpatically.
1 
These drugs include depolarizing or nondepolarizing neuromus-
cular blockers, some antibiotics (e.g., aminoglycosides, macro-
lides, polypeptides, and monobasic amino-acid antibiotics), anti-
convulsants (e.g., phenytoin and trimethadione), β-blockers, 
antiarrhythmic agents, calcium channel blockers, iodinated ra-
diographic contrast agents, magnesium, phenothiazine, lithium, 
and chloroquine.
1 In addition, some drugs are capable of induc-
ing an anti-AChR autoimmune response de novo. Those induc-
ing the autoimmune form of MG include D-penicillamine, in-
terferon (IFN)-α, and pyrithioxine.
1 Physicians should therefore 
ensure that they understand the pharmacokinetic mechanisms 
of these drugs and take into consideration their potential serious 
effects when determining treatment regimens.
Immunomodulating Treatments
Rapid induction of remission
AChEIs do not affect the production of auto-Abs and merely im-
prove MG symptoms. The initial aim in the treatment of progres-
sive MG should be to actively modulate the derangement of the 
immune system as soon as possible. Plasma exchange (PE) and 
IVIg have been used to induce rapid improvement of myasthe-
nia symptoms because they work within days to 1 or 2 weeks af-
ter initiation.
1 Therefore, they are useful during acute worsen-
ing of myasthenia, including myasthenic crisis and in the perio-
perative period. However, their effects are short-term (generally 
1-2 months), and other ISs are usually necessary to maintain a 
state of remission.
1-3
Intravenous	immunoglobulin
IVIg, a blood product composed of pooled immunoglobulin G 
(IgG) from blood donors, has been used to treat many immune 
deficiencies or autoimmune disorders. IVIg acts on the immune 
system in various ways, including accelerating the catabolism 
of IgG, suppressing Ab production and neutralizing auto-Abs by 
anti-idiotypic Abs, inhibiting complement activation and mem-Kim JY et al.
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brane attack complex formation, and inhibiting Fc receptor func-
tion.
4 The improvement rate associated with IVIg has been re-
ported to be more than 70%.
5
Table 1 provides a summary of randomized clinical trials in-
volving IVIg. Wolfe et al.
6 compared the efficacy of IVIg with 
that of a placebo in a small number of MG patients (six patients 
receiving IVIg and nine receiving placebo). Their randomized, 
open-label trial revealed a positive trend for IVIg after 6 weeks.
6 
One large, randomized, placebo-controlled trial conducted in 
patients with worsening weakness produced the promising find-
ing that IVIg improved muscle strength (class I evidence).
7 Two 
randomized controlled trials found no significant difference be-
tween the efficacies of IVIg and PE, although IVIg therapy was 
less toxic.
8,9 Accordingly, it has been accepted that while their 
treatment efficacies are similar, IVIg is a safer option than PE. 
A single trial found that IVIg was superior to placebo for the 
treatment of MG exacerbations.
7
IVIg is generally given at a total dose of 2 g/kg over 3 or 5 
days. Large, randomized, double-blind trials did not show that 
IVIg therapy for two successive days was better than 1-day IVIg 
and 1-day placebo therapy.
10 Its therapeutic effect appears with-
in a couple of days from the initiation of treatment and lasts at 
least for several weeks, and usually up to 2 months.
1 Most of 
the common adverse effects are mild and known to be related 
to the infusion process: headache, chills, myalgia, chest discom-
fort or shortness of breath can occur early in infusion, and are 
usually relieved by slowing of the infusion rate.
1 Some patients 
exhibit skin reactions, such as urticaria or erythematous rash, 
which can develop up to a few days after infusion.
4 In rare cases 
it causes more serious side effects, such as aseptic meningitis, 
proteinuria, or acute renal tubular necrosis in patients with un-
derlying renal disease, and thromboembolic events including 
myocardial infarction, pulmonary embolism, and stroke result-
ing from increased plasma viscosity.
1,4 Severe anaphylaxis might 
also occur in patients with a severe IgA deficiency.
1,4
Plasma	exchange
PE is an extracorporeal blood purification technique. The basic 
mechanism of PE is the rapid elimination from the plasma of a 
large amount of causative auto-Abs and other humoral media-
tors including cytokines and immune complexes.
11 Although ran-
domized controlled trials regarding the efficacy of PE in MG 
are lacking, PE is considered an established therapeutic option 
for preoperative preparation and MG crisis (class III evidence).
11 
The clinical efficacy of PE varies from 55% to 100%.
12 The stan-
dard method is to remove 2-3 L of plasma three times a week or 
every other day for five procedures.
1,3 In most patients, clinical 
improvement occurs after two to three procedures and usually 
lasts for 1-2 months.
12 Adverse effects include some side effects 
related to the central venous catheter, such as pneumothorax, 
thrombosis, or catheter-related infection, and others related to 
the replacement fluids and anticoagulant including hypocalce-
mia, acid-base imbalance, and bleeding.
1,12 More serious side 
effects include anaphylaxis and transfusion-related infection.
1,12
The newly developed procedures of double-filtration plasma-
pheresis (DFPP) and immunoadsorption (IA) techniques have 
been tested with a view to reducing unwanted adverse effects and 
more selective removal of circulating Abs. DFPP utilizes two fil-
ters; the first filter separates plasma from blood and the second 
separates albumin from larger molecules including immuno-
globulins, immune complexes, and lipoproteins.
12 DFPP requires 
the instillation of less albumin solution as a replacement fluid 
than does classical PE, thus reducing the risk of infection.
12 The 
IA method selectively adsorbs most large proteins such as AChR 
Abs by using an affinity-type adsorbent, tryptophan-linked poly-
vinyl alcohol gel (Immunosorba IM-TR, Asahi Medical, Japan) 
or a staphylococcal protein A column (Excorim, Lund, Swe-
den).
12 Replacement fluids are not required in these methods. 
Table 1. Randomized clinical trials of IVIg in MG
Author
(year)
Subjects Results
Gajdos
(1997)
Patients with 
  exacerbation
IVIg at 0.4 mg/kg for 3 days
  (n=23) or 5 days (n=23) 
Three times PE EOD (n=41) No difference in efficacy, 
  fewer S/E in IVIg
Ronager
(2001)
Moderate-to-severe
  patients on ISs
IVIg at 0.4 mg/kg for 5 days 
  → observation → five times 
  PE EOD → observation (n=8)
Five times PE EOD 
  → observation 
  → IVIg at 0.4 mg/kg for 5 days 
  → observation (n=4)
More rapid onset of 
  improvement after PE but no 
  significant difference 
  in outcome
Wolfe
(2002)
Generalized MG IVIg at 1 g/kg at induction 
  → repeat after 3 weeks (n=6)
5% albumin placebo 
  → repeat after 3 weeks (n=9)
Positive trends in IVIg 
  after 6 week open-label study
Gajdos
(2005)
Patients with 
  exacerbation
IVIg at 1 g/kg on day 1 
  → placebo on day 2 (n=81)
IVIg at 1 g/kg for 2 days (n=87) No significant difference
Zinman
(2007)
Patients with 
  worsening condition
IVIg at 2 g/kg divided 
  over 2 days (n=24)
IV 5% dextrose in water 
  (2 g/kg; n=27)
Improvement in QMG Score 
  in IVIg group (class I evidence)
IVIg: intravenous immunoglobulin, MG: myasthenia gravis, EOD: every other day, S/E: side effect, QMG: quantitative MG, ISs: immu-
nosuppressants, PE: plasma exchange.MG Treatment
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The clinical efficacy of these methods was reported to be simi-
lar to that of classic PE.
13 Liu et al.
14 recently conducted a ran-
domized, controlled, 3-armed trial comparing DFPP (n=15) and 
IA (n=10) with IVIg (n=15) in 40 patients with late-onset MG. 
They found that both DFPP and IA exhibited better short-term 
clinical effectiveness than IVIg transfusion, rapidly and effec-
tively clearing the pathogenic Abs in their patients.
14 More ran-
domized controlled trials are required to confirm these findings.
Long-term maintenance of remission
Thymectomy
Thymectomy for MG treatment has been performed widely 
since Blalock and his colleagues first reported its usefulness in 
1939.
15 Although there are no randomized controlled trials, clin-
ical experience has led to the general acceptance that thymec-
tomy increases the chances of remission and reduces the risk of 
long-term IS treatment. Thymectomy remains a generally accept-
ed treatment for generalized-MG patients with disease onset be-
fore the age of 50 years.
2 There is disagreement concerning the 
use of thymectomy in children prior to puberty. Some authors 
report favorable results with thymectomy in juvenile MG pa-
tients, whereas others have taken a more cautious attitude in this 
regard for very young children because of the possibility of com-
promising immune function.
16,17 Furthermore, thymectomy is still 
not recommended for the treatment of anti-MuSK-Ab-positive 
patients because they lack pathologic thymic changes.
18,19 How-
ever, there is no sound evidence supporting this. In our opinion, 
thymectomy should be considered first to treat generalized-MG 
patients with thymic abnormality with onset between the ages 
of puberty and around 50 years.
Many studies suggest that the earlier in the course of the ill-
ness that thymectomy is performed, the better the treatment re-
sults are, especially within the first 2 years of the disease.
2,20 The 
therapeutic effect of thymectomy generally occurs after about 
1 year, and remission is most likely in the period 5-10 years af-
ter the surgery.
2,20 The reported complete remission rate after 
thymectomy has varied from 8.3% to 53.1%.
20,21 Several pro-
cedures are used to remove the thymus, including transsternal, 
transcervical, transsternal-transcervical “maximal”, and video-
assisted thoracoscopic surgery (VATS) approaches. The standard 
and preferred approach has been via sternotomy, but minimally 
invasive VATS is becoming popular due to the associated short 
hospitalization, low operation-related mortality and morbidity, 
and cosmetic advantage. Meyer et al.
22 compared the outcomes 
of extended transsternal thymectomy (n=47) and VATS (n=48), 
and found that 95.8% of the VATS group and 97.9% of the trans-
sternal group were in complete stable remission, pharmacologic 
remission, or minimal manifestations state after the procedure. 
Meyer et al.
22 concluded that these approaches resulted in equiv-
alent outcomes. Further large, randomized studies are neces-
sary to provide a more complete comparison of the relative ther-
apeutic efficacies of the different thymectomy procedures.
Corticosteroids
CSs are universally used as the first-line IS for inducing com-
paratively rapid remission and bridging to long-term mainte-
nance therapy using other ISs until they take effect. The mecha-
nism of action of CSs in MG is poorly understood. The effects 
on the immune system involve several important pathways, in-
cluding 1) reducing the distribution and trafficking of leuko-
cytes, 2) specific inhibition of the recruitment and migration of 
lymphocytes to an inflammatory site, 3) blockade of various T-
cell functions, 4) reducing the production and secretion of cy-
tokines and other immune mediators from macrophages or T 
cells, and 5) decreasing the maturation of dendritic cells.
23 The 
high doses generally used to induce a remission can also induce 
apoptosis of various immune cells. 
Several studies of CSs in MG found that remission or a marked 
improvement occurs in an approximately 80% of cases.
24 Ta-
ble 2 lists the randomized clinical trials of CSs performed to 
date. The only adequately sized randomized controlled trial, 
which was conducted in 1964, compared administration of ad-
renocorticotrophic hormone with placebo in 43 ocular-MG pa-
tients, and found no significant difference between the two.
25 
That study was flawed by its short follow-up time and failure to 
take into account the temporary worsening of MG that occurs 
1-2 weeks after initiating high-dose steroid therapy. A small ran-
domized study of 13 severe-MG patients found no clinical dif-
ference between 100-mg prednisone (PD; 6 patients) and pla-
cebo (7 patients) administered on alternate days.
26 However, that 
study involved only a small number of subjects and failed to pro-
Table 2. Randomized clinical trials of CSs in MG
Author (year) Subjects Results
Mount 
(1964)
Ocular MG ACTH at 580 units 
  over 8 days (n=21)
Placebo (n=22) No significant difference after 3 months
Howard 
(1976)
Moderately 
severe MG
PD at 100 mg
  on every other day (n=6)
Placebo (n=7) No clinical difference after 6 months
Lindberg 
(1998)
Moderate MG IV MP at 2 g 
  for 2 days (n=10)
Placebo (n=10) Significant improvement of muscle score 
  in the steroid group for 14 weeks
CSs: corticosteroids, MG: myasthenia gravis, ACTH: adrenocorticotrophic hormone, PD: prednisone, MP: methylprednisolone.Kim JY et al.
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vide detailed clinical data. In a double-blind, placebo-controlled 
study comparing IV methylprednisolone and placebo in 20 
patients, the IV methylprednisolone group exhibited a signifi-
cant improvement in myasthenic muscle score, while the pla-
cebo group did not (class I evidence with limited power).
27
The oral administration of CSs at a dose of 1 mg/kg is com-
monly used for the rapid improvement of myasthenic symp-
toms. It is noteworthy that high-dose steroids can temporarily 
exacerbate myasthenia symptoms in some patients, the so-called 
steroid dip, which usually occurs 4-14 days after initiation and 
lasts for less than 1 week.
1-3 Hospitalization and close monitor-
ing for respiratory insufficiency may be needed for the prompt 
management of steroid-induced worsening, and IVIg or PE can 
be used to prevent or reduce the risk of this occurring when high-
dose steroid therapy is commenced. To avoid this exacerbation, 
some physicians titrate up the doses of steroid slowly or admin-
ister the medication on an every-other-day schedule.
The many severe side effects of long-term use of steroids mean 
that this should be avoided. Common side effects are Cushing’s 
syndrome, osteoporosis, weight gain, hyperglycemia, diabetes, 
hypertension, gastritis or ulcer, skin fragility, anxiety/depression/
insomnia (steroid psychosis), avascular necrosis of the joints and 
steroid myopathy.
Long-term	periodic	intravenous	immunoglobulin
IVIg has been used chronically when patients show an excellent 
response to IVIg and are contraindicated or unsuitable for ISs. In 
this case IVIg is administered as two or three infusions every sev-
eral weeks. Wegner and Ahmed
28 described a small clinical trial 
with long-term IVIg monotherapy in six anti-AChR-Ab-posi-
tive patients. All of the patients received an initial infusion of IVIg 
at a dosage of 400 mg/kg/day for 5 days followed by mainte-
nance therapy of 400 mg/kg for 1 day every 3-4 months. After a 
follow-up period of 2 years, all of the patients maintained good 
functional status without any deterioration or IVIg-related side 
effects.
28 If there is no subordinate restriction, including the high 
cost of IVIg therapy, long-term periodic IVIg may be a good option 
for MG patients who are unsuitable for steroid or other ISs.
Blocking	the	synthesis	of	DNA	and	RNA
Azathioprine
Azathioprine (AZA) is a DNA-synthesis inhibitor that inhibits 
the synthesis of purines (adenosine and guanine). It is a prodrug 
that is metabolized to several active metabolites: 6-mercapto-
purine, followed by 6-thiouric acid, 6-methyl-mercaptopurine, 
and 6-thioguanine.
23 These metabolites compete with the purine 
derivative hypoxanthine, and are incorporated into replicating 
DNA, consequently blocking DNA and RNA synthesis.
23 AZA 
mainly affects the actively proliferating cells, including lympho-
cytes, and is thus used as one of the main drugs in organ trans-
plantation and autoimmune disease.
Treatment of MG with AZA is associated with a good out-
come, and its effectiveness has been reported to be more than 
75%.
29,30 Table 3 summarizes the randomized clinical studies of 
AZA. A few randomized trials of AZA found no significant dif-
ferences between AZA and CS in improving MG.
31,32 Palace et 
al.
31 carried out a randomized, double-blind trial of AZA plus 
PD versus placebo plus PD in 34 generalized-MG patients, and 
found no significant difference between the two groups with re-
gard to muscle strength scores and median PD dosage at 12 
months. However, the median PD dose at 36 months was sig-
nificantly reduced and the duration of remission was signifi-
cantly longer in the AZA and PD group.
31 Therefore, although 
this (class I) trial showed no added effectiveness of AZA in in-
ducing remission, it did demonstrate its effectiveness as a ste-
roid-sparing agent capable of reducing the side effects of CSs.
The initial dosage of AZA is 1 mg/kg/day with two divided 
doses, gradually increasing to 2-3 mg/kg/day. Its effect is gen-
erally noted 3 months after the initiation of treatment. AZA has 
been used widely in MG because it has fewer side effects than 
CSs. Common side effects are nausea, vomiting, rash, hepato-
toxicity, pancreatitis, leukopenia, and thrombocytopenia.
1 There-
fore, regular checkup of the complete blood count (CBC), liver 
function, and amylase is necessary. The CBC needs to be mon-
itored weekly during the first month, monthly for the following 
year, and then every 3-6 months thereafter.
1 If the total white 
Table 3. Randomized clinical trials of AZA in MG
Author (year) Subjects Results
MG Clinical 
  Study Group
  (1993)
Generalized MG AZA + initial PD (n=21)
  (AZA at 3 mg/kg/day →
  2 mg/kg/day; PD at
  1 mg/kg/day → tapered)
PD (n=20)
  (1 mg/kg/day →
  0.5 mg/kg/day →
  0.25 mg/kg/day)
No significant differences 
  in muscular score and 
  functional grade, but higher
  failure rate in PD group
Palace
  (1998)
Generalized MG AZA + PD (n=15)
  (AZA at 2.5 mg/kg/day; PD 
  at 1.5 mg/kg or 100 mg EOD, 
  maintained until remission, 
  then tapered)
Placebo + PD (n=19)
  (PD at 1.5 mg/kg or 100 mg 
  EOD, maintained 
  until remission, then tapered)
Reduced PD dose in AZA 
  group and higher relapse 
  and failure rates 
  in placebo group
AZA: azathioprine, MG: myasthenia gravis, PD: prednisone, EOD: every other day.MG Treatment
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blood cell count drops to less than 3,000/μL, AZA should be dis-
continued for a few days and adjusted to keep the white blood 
cell count at more than 4,000/μL.
33 It is also important to bear in 
mind the risk of opportunistic infection and malignancy during 
long-term treatment. About 10% of the general population have a 
deficiency of thiopurine 5-methyltransferase, which is the enzyme 
that blocks the formation of 6-thioguanine nucleotides, and may 
cause bone marrow suppression at lower doses due to the increased 
toxicity of its metabolites.
23
Mycophenolate mofetil
Mycophenolate mofetil (MyM) is a prodrug of mycophenolic 
acid that inhibits inosine monophosphate dehydrogenase, which 
is the rate-limiting enzyme in the de novo synthesis of guano-
sine nucleotides. The inosine monophosphate dehydrogenase 
enzyme has two isoforms: type I is found in resting cells and type 
II is expressed by activated lymphocytes.
23 The type II isoform is 
more sensitive to inhibition by mycophenolic acid than is the type 
I isoform, and hence MyM acts primarily on activated T- and B-
lymphocytes.
23 As a result, this drug is very specific to activat-
ed lymphocytes.
The half-life of MyM is 16-18 hours, and it is excreted renal-
ly through hepatic metabolism. The administered dosage is start-
ed at 500 mg twice a day orally and then increased to a standard 
dosage of 2,000-3,000 mg/day in two divided doses after 1 week. 
More than 50% of patients respond well to MyM treatment (as 
evidenced by open-label trials).
34 Table 4 summarizes the ran-
domized studies of MyM. A randomized double-blind trial of 
MyM plus either cyclosporine (CyA) or IS versus placebo 
plus either CyA or IS was conducted in 14 MG patients for 5 
months.
35 However, the small number of patients and short study 
duration meant that this study did not provide any meaningful 
results. Two additional randomized, double-blind studies were 
carried out.
36,37 One study compared 2.5 g/day MyM plus 20 mg/
day PD (41 patients) with placebo plus 20 mg/day PD (39 pa-
tients) in 80 IS-naïve patients with mild-to-moderate general-
ized, anti-AChR-Ab-positive MG.
36 The other was an interna-
tional, phase-III trial of 2 g/day MyM versus placebo for 36 
weeks in 176 patients with anti-AChR-Ab-positive class II-IVa 
MG taking CSs for at least 4 weeks.
37 These studies failed to 
demonstrate a clear benefit of MyM in permitting the tapering 
of the dosage of PD.
37 However, a retrospective study recently 
reviewed outcomes and PD dosage for 102 anti-AChR-Ab-pos-
itive MG patients with MyM alone or with PD.
38 In this retro-
spective study, the percentage of patients with a desirable out-
come began to increase after 6 months, and 80% of those 
followed for more than 24 months had a desirable outcome.
38 
After 25 months, 54.5% of patients were able to discontinue PD.
38 
The results of this study suggest that the clinical efficacy of 
MyM begins to appear after 6 months when administered as 
monotherapy or in combination therapy with PD (class IV evi-
dence).
38
Common adverse effects of MyM are gastrointestinal symp-
toms including nausea, vomiting, diarrhea and abdominal cramps, 
headache, fatigue, skin reactions, and viral infections. Rarely 
reported side effects are pure red cell aplasia, progressive mul-
tifocal leukoencephalopathy, and malignancy.
39,40 CBCs should 
be monitored regularly during MyM treatment. MyM is contra-
indicated in pregnant women or women planning to conceive 
due to the risk of miscarriage or congenital malformations.
Cyclophosphamide
Cyclophosphamide (CP), a well-known antineoplastic agent, is 
a prodrug that is converted into an active metabolite (4-hydrox-
ycyclophosphamide) in the liver. It is one of the classic alkylat-
ing agents, adding an alkyl group to the guanine base of DNA, 
leading to cell death.
23 Perez et al.
41 followed up 42 MG patients 
who received a total dose of 7.6-130 g of CP over 2-37 months.
According to their definition (being asymptomatic for at least 
6 months without medication), remission was observed in 12 of the 
16 patients (75%) who were followed for more than 18 months.
41
A randomized, double-blind trial was conducted in 23 MG 
patients with either poor disease control or steroid-related side 
effects, who were given either IV CP plus PD (n=12) or place-
bo plus PD (n=11).
42 CP pulses were given at an initial dose of 
500 mg/m
2 of body surface, and then monthly for the first 6 
months, and finally every other month thereafter.
42 PD was ta-
pered off by 10 mg/month if initially taking more than 50 mg/
Table 4. Randomized clinical trials of MyM in MG
Author (Year) Subjects Results
Meriggioli (2003) Generalized MG MyM (2 g/day)+CyA 
  or PD or no IS (n=7)
Placebo+CyA 
  or PD or no IS (n=7)
Favorable trend in MyM 
  group, but not statistically 
  significant
Muscle Study 
  Group (2008)
Generalized, 
  AChR-Ab positive
MyM (2.5 g/day)+PD 
  (20 mg/day; n=41)
Placebo+PD 
  (20 mg/day) (n=39)
No differences in QMG score 
  and dosage of PD
Sanders (2008) AChR-Ab positive
  class II–IVa MG
MyM (2 g/day)
  (n=88)
Placebo
  (n=88)
No significant difference 
  between the study groups
MyM: mycophenolate mofetil, MG: myasthenia gravis, CyA: cyclosporine, QMG: quantitative MG, PD: prednisone, IS: immunosup-
pressants, AChR: acetylcholine receptors.Kim JY et al.
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day, 5 mg/month if taking 20-50 mg/day, and 2 mg/month if tak-
ing 20 mg/day or less.
42 Significant improvement of muscle strength 
was noticed in the CP group at 12 months, mainly in the bulbar, 
masticatory and extraocular muscles.
42 A significant reduction 
in PD dosage was also reported in the CP group at 6 and 12 months 
compared with the placebo group.
42
Drachman et al.
43 performed a trial called “rebooting the 
immune system” involving high-dose CP for treatment of refrac-
tory MG patients. They followed 12 refractory patients who re-
ceived 200 mg/kg of CP for 1-9 years.
43 Eleven of the 12 pa-
tients exhibited a dramatic clinical improvement from 5 months 
to 7.5 years, and this improvement lasted for more than 1 year 
in 7 patients.
43 They suggested that high-dose CP resulted in ef-
fective remission in most refractory MG patients.
43 Therefore, 
this method could be considered cautiously in severe-MG pa-
tients who are refractory to other ISs. The administered dose is 
3-5 mg/kg orally or 200 mg IV for 5 days. Adverse effects of CP 
include nausea, vomiting, diarrhea, alopecia, darkening of the 
skin and nails, infertility, myelosuppression, oliguria, hemorrhag-
ic cystitis (prevented by large fluid intake and Mesna), opportu-
nistic infection, and malignancy such as bladder cancer.
23,33
                 
Methotrexate
Methotrexate (MTX), an antimetabolite and antifolate drug, in-
hibits the action of dihydrofolate reductase catalyzing the con-
version of dihydrofolate to active tetrahydrofolate. Folic acid and 
folate are necessary for purine and pyrimidine synthesis. There-
fore, MTX ultimately blocks the synthesis of DNA and RNA, 
and has a more potent effect on rapidly dividing cells.
23 Side ef-
fects associated with MTX therapy are gastrointestinal symp-
toms, myelosuppression, mucositis, cystitis, liver fibrosis, cir-
rhosis, and lung fibrosis. Combined administration with folate 
can reduce the risk of myelosuppression.
There have been no published clinical trials for MTX thera-
py in MG patients. MTX is recommended by some experts as 
a second-line IS in other-drug-resistant MG patients.
23
Targeting	T-cells:	calcineurin	inhibitors	
(cyclosporine	A	and	tacrolimus)
Cyclosporine A (CyA) and tacrolimus (FK506) are calcineurin 
inhibitors that bind to the cytosolic proteins, cyclophilins (im-
munophilins), of lymphocytes: CyA binds to cyclophilin and 
FK506 binds to FK506-binding protein.
23,33 Activation of T-cell 
receptors by antigens increases intracellular calcium and induc-
es the activation of calcineurin.
23,33 Activated calcineurin plays 
an important role in the transcription of proinflammatory cyto-
kines including interleukin (IL)-2, IFN-γ, or tumor necrosis fac-
tor alpha (TNF-α) by dephosphorylating the transcription factor, 
nuclear factor of activated T-cells.
23 The CyA-cyclophilin and 
FK506-binding protein complexes block calcineurin, conse-
quently inhibiting T-cell activation and proliferation.
23
Until now, uncontrolled trials of CyA were conducted in se-
vere-MG patients who were unresponsive to thymectomy, ste-
roids, or AZA. About 80% of recruited patients improved after 
CyA treatment.
44,45 The first randomized, placebo-controlled tri-
al showed that the increase in muscle strength was significantly 
greater in the CyA group (n=10) than in the placebo group (n=10) 
at 6 and 12 months.
46 Tindall et al.
47 followed 39 generalized-
MG patients with CyA plus PD versus placebo plus PD. They showed 
that muscle strength was significantly increased in the CyA group, 
but that there was no definite difference in the percentage change 
in the steroid dosage between the two groups at 6 months.
47
CyA administration begins with two divided dosages of 4-6 
mg/kg/day, and can be adjusted to maintain the CyA blood level 
at 100-150 ng/mL after 1 month.
33 Regular check-up for levels 
of blood urea nitrogen and creatinine (Cr) are required, and Cr 
levels should be maintained at less than 150% of the baseline 
value (i.e., before treatment).
33 Adverse reactions of CyA include 
gingival hyperplasia, convulsion, nephrotoxicity, hepatotoxicity, 
peptic ulcer, pancreatitis, hypertrichosis, hypertension, oppor-
tunistic infection, malignancy (especially skin cancer), and pos-
terior reversible encephalopathy syndrome.
23,33,48
The use of FK506 is supported by only a few non-random-
ized and non-controlled studies. Nine (47%) of 19 generalized-
MG patients in an open clinical trial exhibited improvement of 
MG or activities of daily living scores with FK506 at a dosage 
of 3-6 mg/day, and reduction of anti-AChR Ab titers and IL-2 
production at the end of a 16-week period.
49 Ponseti et al.
50 re-
ported the results of a low-dosage FK506 (0.1 mg/kg/day) tri-
al in 212 MG patients: 110 thymectomized, CyA-, and PD-de-
pendent patients; 68 thymectomized patients who started FK506 
and PD early postoperatively (24 hours after surgery); and 34 
patients older than 60 years with nonthymomatous generalized 
MG or in whom thymectomy was contraindicated. Of the entire 
cohort, 13.7% achieved clinically stable remission and 73.8% 
achieved pharmacologic remission.
50 In particular, the results 
were best in subjects who took PD and started FK506 early after 
thymectomy.
50 Furthermore, PD administration was withdrawn 
in 95.1% of all patients.
50 Fk506 is administered orally in two 
divided dosages at 0.05-0.1 mg/kg and adjusted to maintain 
blood levels at 5-15 ng/mL.
33 FK506 is less nephrotoxic than 
CyA. FK506 may be carefully considered for intractable ste-
roid-dependent MG patients.
Targeting	B-cells:	monoclonal	antibody	(rituximab)
Rituximab (RTM) is a chimeric monoclonal Ab against CD20 
antigen on surface pre-B and mature B-cells.
23 It was initially 
used to treat B-cell malignancies, such as non-Hodgkin’s lym-
phoma and large B-cell lymphoma, but its use has been expand-
ed to include autoimmune diseases including rheumatoid arthri-MG Treatment
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tis, systemic lupus erythematosus, and multiple sclerosis.
23
There have been only few, small, non-controlled clinical tri-
als for RTM therapy in refractory MG patients.
51,52 Zebardast et 
al.
51 reported promising results for RTM in six refractory MG 
patients with anti-AChR Abs or anti-MuSK Abs, commenting 
that all patients showed clinical improvement with a reduced 
need for multiple and/or high-dose immunotherapy. Maddison 
et al.
52 recently treated ten patients with generalized MG and two 
with Lambert-Eaton myasthenic syndrome with RTM. One-quar-
ter of the patients achieved remission and 42% improved clini-
cally over 18 months, and hence RTM may be considered as an 
option for refractory patients who are uncontrolled with multiple 
ISs.
RTM is administered intravenously weekly for 2-4 weeks at 
a dose of 375 mg/m
2, as it is used in hematologic malignancies. 
Common side effects are related to the IV infusion: chills, fe-
ver, nausea, and sometimes bronchospasm. Other side effects are 
hepatitis B reactivation and cardiac arrhythmia.
51 There have been 
some reports of progressive multifocal leukoencephalopathy in 
patients taking monoclonal Ab including RTM.
53 This serious 
side effect renders it necessary to pay RTM therapy special 
attention.
New therapeutic trials
Antisense	treatment	(EN101)
Mammalian AChE has three isoforms: synaptic (AChE-S), eryth-
ropoietic, and read-through (AChE-R).
54 AChE-S is bound to 
the muscle basement membrane and is responsible for the rap-
id hydrolysis of ACh at the neuromuscular synapse. AChE-R, 
which plays a role in nonsynaptic ACh hydrolysis and in mor-
phogenesis, is present in much lower amounts but accumulates 
in response to stress.
54 Chronic AChE inactivation by nonselec-
tive AChEIs induces the overexpression of AChE-R.
54 Nonsyn-
aptic ACh hydrolysis by overexpressed AChE-R may result in 
myopathic changes and limit the duration of AChEI to recover 
stable compound motor action potentials and anti-inflammato-
ry responses through cholinergic up-regulation.
54
EN101 (Monarsen) is a synthetic antisense RNA molecule that 
selectively lowers the levels of AChE-R in both blood and mus-
cle by inhibiting the gene expression of AChE-R at the mRNA 
level. EN101 therapy may thus improve muscle strength.
54,55
A phase-Ib open-label clinical trial with oral EN101 was re-
cently undertaken in 16 MG patients, of which 14 exhibited a 
clinical improvement without serious adverse effects.
55 This 
promising result has led to a phase-II trial for this therapy.
Tumor-necrosis-factor-alpha	receptor	blocker	
(Etanercept)
Etanercept, which is an engineered fusion protein linked to 
Fc of IgG1, binds to TNF.
56 TNFα is a typical proinflammato-
ry cytokine produced by macrophages and monocytes. Etaner-
cept blocks the activity of TNFα by acting as a decoy receptor 
binding to TNF.
56 Some clinical trials have been reported in other 
autoimmune diseases including rheumatoid arthritis, Wegener’s 
granulomatosis, and ankylosing spondylitis. Etanercept therapy for 
MG is still in its infancy. Rowin et al.
56 performed an open-label 
trial of 25-mg etanercept twice weekly in 11 steroid-dependent 
MG patients, but found that only 6 patients showed improvement 
after 6 months.
Etanercept may be administered as a subcutaneous injection 
at a dose of 25 mg twice weekly or 50 mg once weekly. It has been 
reported to cause neuromuscular complications, including au-
toimmune peripheral nerve disorders such as chronic inflamma-
tory demyelinating polyradiculoneuropathy, Guillain-Barré syn-
drome, mononeuritis and MG.
57 Further well-organized studies 
are thus required to determine the efficacy and adverse effects of 
this drug in MG.
Experimental	immunotherapies
The complement system, which is a part of the innate immune 
system, consists of classical, alternative, and mannose-binding 
lectin pathways that activate each other.
58 The complement sys-
tem plays an important role in host defense against bacteria and 
viruses, interfacing between innate and adaptive immunity, lead-
ing to clearance of immune complexes and apoptotic cells.
58 Since 
MG is fundamentally an autoimmune disease mediated by au-
to-Abs, complement plays an important role in the Ab-mediat-
ed destruction of neuromuscular synapses. A recent study of the 
animal model of MG, experimental autoimmune myasthenia gra-
vis, yielded promising results for the efficacy of the C5 comple-
ment inhibitor, rEV576.
59 The complement inhibitor might thus 
be expected to be a new therapeutic choice in MG.
Other experimental immunotherapies are being investigated, 
including adoptive cellular gene therapy, genetically engineered 
antigen-presenting cells, syngeneic AChR fragments, and pre-
ventive strategies using RNA aptamer.
Strober et al.
60 recently reported the case of a 17-year-old boy 
with severe, refractory MG. He was previously undercontrolled 
with IVIg, CSs, thymectomy, AZA, MyM, plasmapheresis, RTM, 
and high-dose CP. He was treated with allogenic hematopoiet-
ic stem cell transplantation, and his weakness completely re-
solved at 40 months posttransplantation.
60
Conclusions and Recommendations
The treatment of MG should be tailored according to the clini-
cal manifestations or subtypes, functional impairment, medical 
state, and activities of daily living of individual patients. As men-
tioned above, in progressive MG it is desirable to block the ab-Kim JY et al.
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normal immunologic process as soon as possible while mini-
mizing the adverse reactions of therapy.
Fig. 1 summarizes our recommendations. Thymectomy may be 
considered preferentially in postpubertal generalized-MG pa-
tients with a stable medical condition, if thymoma is discovered 
on chest computed tomography. Symptomatic treatment with 
AChEI might be sufficient in ocular-MG patients. In uncontrolled 
cases with sufficiently large amounts of AChEI, steroids might 
be considered. If the response to steroids is incomplete, a first-
line IS, such as AZA or MyM, may be added.
If generalized-MG patients has moderate to severe symptoms, 
IV high-dose steroids may be recommended for rapid induction 
of remission. Simultaneous IVIg infusion or hospitalization would 
be required due to the risk of transient aggravation during the 
early days after steroid administration. The high dose should be 
maintained until remission or minimal manifestations are attained, 
and then slowly tapered to the minimal effective dose. It is ad-
visable to start calcium supplements and vitamin D and possi-
bly bisphosphonates with steroid administration. Once adequate 
reduction of steroids is obtained, first-line IS (AZA or MyM) may 
be added with the purpose of steroid-sparing. If myasthenic symp-
toms are aggravated during tapering steroids, dose reduction 
should first be suspended, holding the dose steady for a few days. 
If the symptoms progress continuously or fail to improve, it will 
be necessary to increase the CS dose considerably, at which time 
a slight change would not help to secure a remission. An alterna-
tive is to treat the patient with a course of IVIg, which may result in 
a long-term return to remission. Once a remission is achieved again, 
tapering is retried more slowly than before and, if the patient has 
not been on ISs before, starting this form of treatment should also 
be carefully considered.
Current therapeutic modalities for MG have reduced the as-
sociated mortality and morbidity dramatically. Although advanc-
es in critical-care medicine have taken the lead in this progres-
sion, immunomodulating therapies have accelerated the impro-
vement. CSs are the mainstay of immunotherapies for MG, but 
Suspected MG patient
Generalized-MG
Thymic abnormalities?
Cholinergic crisis
AChEI, if mild symptoms
IV High-dose steroids
Steroid tapering & 1st line
ISs (AZA, MyM)
2nd line ISs (CP, CyA, FK506,
MTX) or Periodic IVIg
3rd line ISs
(RTM, High-dose CP)
Thymectomy if it is not
contraindicated
OcuIar-MG?
Thymectomy (optional)
AChEI
Steroids
Uncontrolled
Uncontrolled
Uncontrolled
Uncontrolled
Yes
Yes
Yes
No
No
No
Electrophysiologic &
Serologic test, Tensilon or
Stigmine test, Chest CT
Generalized-MG with
quadriparesis,
respiratory failure
Bradycardia, miosis, large
amount of secretion are
combined?
Airway management,
IVIg or plasma exchange
Airway management,
Reduction of AChEI dosage
Fig. 1. The management of MG according to symptoms. MG: myasthenia gravis, ISs: immunosuppressants, AZA: azathioprine, MyM: my-
cophenolate mofetil, CP: cyclophosphamide, CyA: cyclosporine, IVIg: intravenous immunoglobulin, RTM: rituximab.MG Treatment
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the side effects are considerable. Similarly, other ISs have many 
potentially serious side effects. Therefore, the development of 
more effective and safer ISs is a pressing issue. Various ISs that 
act on the immune system more specifically are being studied. 
The ideal model might be immunotherapy that can control se-
lectively the AChR-specific T-cell immune response of MG.
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